Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer

The addition of bevacizumab to chemotherapy has prolonged overall and progression-free survival rates for metastatic colorectal cancer (mCRC). However, KRAS-mutant (KRAS-mut) CRC, lacking an ideal targeted agent, represents an inferior-response subgroup of patients. In the present study, we investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Longhui, Wang, Rong, Wang, Yanxia, Peng, Shunli, Ma, Yueyun, Ding, Sijie, Yang, Hong, Chen, Shiyu, Luo, Xiaoqing, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339053/
https://www.ncbi.nlm.nih.gov/pubmed/32629177
http://dx.doi.org/10.1016/j.neo.2020.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339053/
https://www.ncbi.nlm.nih.gov/pubmed/32629177
http://dx.doi.org/10.1016/j.neo.2020.06.001

Ejemplares similares